Why Cuban’s Cost Plus Drugs Works for Generics—But Brand Drugs Are a Different Fight Entirely
Mark Cuban built his fortune by spotting inefficient markets and charging in with a simpler model. The Dallas Mavericks. HDNet. […]
How Cost Plus Drugs Exposes Drug Pricing Secrets Your Competitors Don’t Want You to Know
In January 2022, Mark Cuban launched a pharmacy that listed drug prices on a public website. That alone was unusual.
How Cost Plus Drugs Exposes Drug Pricing Secrets Your Competitors Don’t Want You to Know Read Post »
Mark Cuban’s Generic Drug Play: Who Gets Disrupted First?
Mark Cuban built a $5.8 billion fortune buying and selling assets that others undervalued. In January 2022, he turned that
Mark Cuban’s Generic Drug Play: Who Gets Disrupted First? Read Post »
Patent Deals Predict Biotech Hiring: How to Read Licensing Signals Before the Jobs Post
The press release drops at 7 a.m. Eastern. A mid-cap biotech has just signed a license agreement with a major
Patent Deals Predict Biotech Hiring: How to Read Licensing Signals Before the Jobs Post Read Post »
Reformulated Drugs, Real Money: How Pharma Prices Its Way Past Patent Cliffs
The molecule did not change. The price did. When AstraZeneca introduced esomeprazole — branded as Nexium — in 2001, it
Reformulated Drugs, Real Money: How Pharma Prices Its Way Past Patent Cliffs Read Post »
Drug Pricing Transparency Is More Dangerous Than Price Cuts
The real disruption isn’t lower prices—it’s visible margins Pharmaceutical executives have spent the better part of two decades preparing for
Drug Pricing Transparency Is More Dangerous Than Price Cuts Read Post »
Mark Cuban’s Cost Plus Drugs vs. Big Pharma: The Strategic War You Need to Be Modeling Right Now
Mark Cuban did not build a pharmacy. He built a mirror and pointed it at an industry that had never
How Pharma Companies Track IND/NDA Dates to Win Global Patent Extensions
The difference between a blockbuster drug that earns another five years of protected revenue and one that faces generic competition
How Pharma Companies Track IND/NDA Dates to Win Global Patent Extensions Read Post »
How Pharma Companies Track IND/NDA Dates to Win Global Patent Extensions
The difference between a blockbuster drug that earns another five years of protected revenue and one that faces generic competition
How Pharma Companies Track IND/NDA Dates to Win Global Patent Extensions Read Post »
